Search results

saxagliptin + metformin (Komboglyze)

Adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type 2 diabetes mellitus inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of saxagliptin and metformin as separate tablets.

empagliflozin/metformin (Synjardy)

in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control / in patients inadequately controlled on their maximally tolerated dose of metformin alone / in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin / in patients already being treated with the combination of empagliflozin and metformin as separate tablets.

dapagliflozin + metformin (Xigduo)

in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: in patients inadequately controlled on their maximally tolerated dose of metformin alone;in combination with other glucose-lowering medicinal products, including insulin, in patients inadequately controlled with metformin and these medicinal products; n patients already being treated with the combination of dapagliflozin and metformin as separate tablets.

linagliptin + metformin (Jentadueto)

for the treatment of adult patients with type 2 diabetes mellitus in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control when insulin and metformin alone do not provide adequate glycaemic control.

saxagliptin metformin (Kombogylze)

In combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type 2 diabetes mellitus when the maximally tolerated dose of both metformin and the sulphonylurea does not provide adequate glycaemic control.

alogliptin plus metformin (Vipdomet)

in the treatment of adult patients aged 18 years and older with type 2 diabetes mellitus: as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin, in combination with pioglitazone (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone, in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.

vildagliptin / metformin hydrochloride (Eucreas®)

Treatment of type 2 diabetes mellitus: in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulphonylurea - in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.

sitagliptin plus metformin (Janumet 50/1000)

In combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.

sitagliptin/metformin (Janumet)

Type 2 diabetes

metformin (Glucophage SR)

Type 2 diabetes mellitus

vildagliptin/metformin (Eucreas)

Type 2 diabetes

canagliflozin plus metformin (Vokanamet)

In adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control

metformin hydrochloride (Glucophage)

Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with impaired glucose tolerance and/or impaired fasting glucose, and/or increased HbA1C who are: • at high risk for developing overt type 2 diabetes mellitus and • still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months.

Metformin hydrochloride (Glucophage SR®)

Type-2 diabetes mellitus

Metformin hydrochloride (Glucophage SR®)

Type-2 diabetes mellitus